Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial show investigational treatment with epcoritamab in combination with…
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of…
After a thorough clinical review, the benefit-risk for the use of Elevidys in non-ambulatory patients with Duchenne has been re-assessed,…
11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in…
June 14, 2025 01:05 ET | Source: Avricore Health Inc. VANCOUVER, British Columbia, June 14, 2025 (GLOBE NEWSWIRE) -- AVRICORE…
June 13, 2025 16:52 ET | Source: Vaxart, Inc. SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart,…
DEFENDANT RALPH NAVARRO/FYI YACHTSClass Action Lawsuit Filed Against RALPH NAVARRO and FYI YACHTS for Alleged Fraud, Racketeering, and Consumer AbuseMIAMI,…
WEST HOLLYWOOD, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- In the heart of Los Angeles’s iconic Sunset Strip, Sunset Social…
Aggregated presentation by day and by market Statement of transactions in own shares from June 2nd to June 6th 2025 Name…
Hapbee Also Updates Status of Audited Financial Statements June 12, 2025 17:00 ET | Source: Hapbee Technologies, Inc. VANCOUVER, British…